Last reviewed · How we verify
NCT05725213
ADL-PDT Under Routine Clinical Conditions in Patients With Actinic Keratosis
trial testing Metvix® 160 mg/g Creme in Actinic Keratoses in 224 participants. Completed in 30 October 2023.
30 October 2023
Quick facts
| Lead sponsor | Galderma Laboratorium GmbH |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 224 |
| Start date | 1 November 2022 |
| Primary completion | 30 October 2023 |
| Estimated completion | 30 October 2023 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Metvix® 160 mg/g Creme — full drug profile →
Conditions studied
- Actinic Keratoses — all drugs for Actinic Keratoses →
Sponsor
Galderma Laboratorium GmbH — full company profile →
Who can join
18 and older, any sex, with Actinic Keratoses. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this non-interventional study (NIS) is to gain comprehensive insights into the practicability of ADL-PDT with Metvix® in patients with actinic keratoses under real-world conditions.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Artificial daylight photodynamic therapy using methyl aminolaevulinate in a real-world setting in Germany: results from the noninterventional study ArtLight.
Philipp-Dormston WG, Brückner M, Hoffmann M, Baé M, et al · · 2025 · cited 4× · PMID 39509708 · DOI 10.1093/bjd/ljae437 -
Photoaging and Cosmetic Result with Artificial Daylight Photo-dynamic Therapy Using Methyl Aminolevulinate.
Szeimies RM, Brückner M, Hoffmann M, Baé M, et al · · 2025 · PMID 40263972 · DOI 10.2340/actadv.v105.43245
Verify or expand the search:
- PubMed search for NCT05725213
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Actinic Keratoses
Currently open trials in the same condition.
- NCT06499415 — Combination Therapy of 5-Fluorouracil and CALcipotriol Versus 5-Fluorouracil in the Treatment of Actinic Keratosis · Phase 4 · recruiting
- NCT06385340 — Investigation of the Effect of Lipikar Baume AP+M · NA · recruiting
- NCT06321003 — SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography · recruiting
- NCT05202860 — Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis · Phase 2 · active not recruiting
- NCT05976061 — High- and Low-risk Actinic Keratosis Referrals to Secondary Care · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05725213 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Galderma Laboratorium GmbH
- Last refreshed: 23 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05725213.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing